NCT02934568 2026-04-16
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT07405801 2026-04-06
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT07054190 2026-03-31
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT04417621 2026-03-12
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis
Phase 2 Active not recruiting
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03078751 2021-10-11
EarLEE-1
Novartis
Phase 2 Completed
NCT02300987 2020-10-26
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT01919229 2016-01-01
MONALEESA-1
Novartis
Phase 2 Terminated